Pages
- About EASL
- Abstracts
- Accommodation/hotel
- Accreditation
- Acknowledgements
- AV recording policy
- Basic science seminar
- Breakfast morning rounds
- Bursaries
- Codes & Manuals
- Contact ILC 2019
- Disclaimer
- Downloadable slide decks
- EASL awards
- EASL General Assembly elects new Board and Committee members
- EASL Governing Board
- ebooks
- Embargo policy
- Exhibition floor plan
- FAQs for journalists
- Grand rounds
- Guidelines for oral presenters
- Guidelines for poster presenters
- Home
- ILC 2018 Debriefs
- ILC 2019 – Registration
- ILC 2019 Congress Review
- Industry news
- Key dates
- Latest news
- Liver transplantation sessions
- Media invitation/registration
- Meet the experts
- Mobile app
- Nurses and Allied Health Professionals sessions
- Opening hours
- Partnership & Exhibition Prospectus
- Photo galleries from ILC 2019
- Posters
- Postgraduate course
- Press Conference Schedule
- Press office
- Press release guidelines
- Principles and values 2019
- Privacy policy
- Programme overview
- Pros & cons sessions
- Public health sessions
- Research think tanks
- Sitemap
- Skills in hepatology
- Solve the case
- State-of-the-art lectures
- State-of-the-art lectures Copy
- State-of-the-art lectures Copy
- Travel information
- Venue/floor plans
- Videos from ILC 2019
- Welcome messages
- What is ILC?
The International Liver Congress™ 2019 news
Posts by category
- Category: Congress News
- ILC DAILY NEWS – SUNDAY RECAP
- ILC DAILY NEWS – SATURDAY RECAP
- ILC DAILY NEWS – FRIDAY RECAP
- Experts warn of fatty liver disease in young people
- ILC DAILY NEWS – THURSDAY RECAP
- Hepatitis B Cure Not a Pipe Dream
- ILC DAILY NEWS – WEDNESDAY RECAP
- ILC DAILY NEWS – WHAT’S IN STORE AT ILC 2019
- CME Credits for ILC 2019
- ILC 2019 Postgraduate course
- EASL members benefit from reduced fees to ILC 2019
- ILC 2019 abstract submission deadline has been extended!
- Nurses are invited to ILC 2019
- YI award application deadline has been extended
- Abstract submission is open – submit yours today
- EASL governing board announces new Vice-Secretary
- See you in Vienna, 10-14 April 2019!
- Press can register for free
- EASL members get reduced fees to ILC 2019
- Category: Industry news
- Category: Press release
- Elafibranor demonstrates significant anticholestatic effects in the treatment of primary biliary cholangitis
- Bulevirtide shows promise in the treatment of chronic hepatitis B/D (HBV/HDV) coinfection
- SMART-C study suggests simplified monitoring of direct-acting antiviral treatment in hepatitis C is possible
- Nivolumab and pembrolizumab display anti-tumour activity and adequate tolerance in ‘real-world’ studies in carcinoma
- Emricasan fails to meet primary endpoint in ENCORE-PH study but shows potential benefits in high-risk individuals
- Integration of hepatitis B virus into the human genome is a common occurrence in HBeAg-negative chronic infection
- Givosiran and lanreotide produce encouraging results in studies of rare liver diseases
- Tenofovir associated with a lower risk of hepatocellular carcinoma than entecavir in large hepatitis B study
- ‘Real-world’ effectiveness of elbasvir/grazoprevir confirmed in people with hepatitis C virus infection who inject drugs and/or receive opioid substitution therapy
- Burden of alcohol-related liver disease on the increase in Canada: are alcohol harm reduction strategies failing?
- Hepatitis B core protein inhibitor, ABI-H0731, produces promising results in Phase 2a studies
- Calmangafodipir may reduce liver injury after paracetamol overdose: final results from the POP trial
- Nonalcoholic fatty liver disease found in large numbers of teenagers and young adults: is a public health crisis looming?
- Glecaprevir/pibrentasvir (G/P) is effective and well tolerated in large ‘real-world’ studies in individuals with hepatitis C virus (HCV) infection
- MSDC-0602K shows potential for improving markers of liver disease in individuals with nonalcoholic steatohepatitis (NASH)
- First-in-class small molecule eliminates cccDNA in the hepatitis B virus (HBV)-infected liver
- Faecal microbiota capsules effective and well tolerated in individuals with recurrent hepatic encephalopathy
- HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease
- Autoimmune diseases of the liver may be partly triggered by exposure to an environmental factor
- Homelessness may be a barrier to success for hepatitis C ‘Treatment as Prevention’ programmes
- High rates of liver disease progression and mortality observed in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH)
- High cost of advanced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) revealed but screening high-risk patients may not be cost effective
- Obeticholic acid improves liver fibrosis and other histological features of nonalcoholic steatohepatitis (NASH)
- ‘Real-world’ experience confirms effectiveness of sofosbuvir/velpatasvir/voxilaprevir in people with chronic hepatitis C (HCV) infection failing direct-acting antivirals (DAAs)